Abstract
MK801 (MK), an N-methyl-d-aspartate (NMDA) receptor antagonist, attenuates tolerance to spinal opioids. Whether this applies to other G-protein-coupled receptor systems is unknown. This study examines the effects of continuous spinal MK on tolerance to the antinociceptive effect of continuous spinal infusion of thealpha-2 agonist ST91 (ST). Intrathecal (i.t.) infusion pumps were implanted in rats which delivered for 7 days: saline (1 μl/h); ST (40 nmol/μl/h); MK (10 nmol/μl/h) + ST (40 nmol/μl/h); or MK (10 nmol/μl/h). Antinociception was measured daily on the hot plate. On day 8, groups received i.t. boluses of ST to generate dose-response curves. A separate ST-infused group received MK (10 nmol i.t.) on day 7. Each group received ST (40 nmol i.t.) 7 days after discontinuation of infusion. Co-infusion of MK with ST resulted in attenuation of the right shift in dose response seen in ST-infused rats and a small preservation of effect on daily testing. However, MK-infused rats showed a significant left shift in ST dose response. Acutely administered, MK did not restore ST sensitivity. One week after cessation of infusion, ST and ST + MK groups showed shorter duration of effect after i.t. ST bolus than controls. In conclusion, chronic spinal MK partially attenuates loss of sensitivity to chronic spinal ST. This supports the hypothesis that opioid- and adrenoceptor-induced tolerances are similarly modulated by the NMDA receptor. However, the increased sensitivity induced by MK alone suggests that NMDA receptor antagonism may not prevent the development of tolerance itself but may alter the expression of tolerance by inducing sensitivityvia other alterations in cellular function.
Footnotes
-
Send reprint requests to: Stuart Dunbar, MB. Research Fellow, Department of Anesthesiology 0818, University of California, San Diego, 9500 Gilman Drive, LaJolla, CA 92103.
-
↵1 This work was supported by DA02110 (T.L.Y.) and by Anesthesiology Training grant NIH T32NS07329 (S.D.).
- Abbreviations:
- MK
- (+)MK801 (dizocilpine hydrogen maleate)
- ST
- ST-91 HCL (2-[2,6-diethylphenylaminol]-2-imidazoline
- intrathecal
- i.t
- NMDA
- N-methyl-d-aspartate
- %MPE
- percentage maximum effect
- %AUC
- percentage area under the dose-response curve
- ANOVA
- analysis of variance
- GTP
- guanine triphosphate
- Received July 30, 1996.
- Accepted February 12, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|